GoAI
Get started
Erasca, Inc. logo

Erasca, Inc.

ERAS

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$17.63

+$0.55 · +3.22%

Aug 21, 4:00 PM ET

Pre-market

$17.31

−$0.32 · -1.82%

Aug 24, 4:20 AM ET

ERAS company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

29

Expensive

Momentum

63

Gaining

Sentiment

50

Mixed

Risk resilience

53

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Jonathan E. Lim
Listed since
Jul 16, 2021
Employees
103

Market position

Day range

Current $17.63

52-week range

Current $17.63

Open
$17.37
Previous close
$17.08
Volume
2.45M
0.41× average
Average volume
5.9M
Average daily volume
Market cap
6.12B USD
Beta
0.65
Market reference 1
50-day average
$17.6598
-0.17% below average
200-day average
$12.0856
+45.88% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-18.56×
P/B (TTM)
15.17×
P/S (TTM)
0×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%

Financial health

Debt / equity
0.12×

Earnings

EPS beat rate
45%
5 beats, 4 misses, 2 met estimates
Average EPS surprise
-42.37%
11 comparable reports
Latest EPS result
-0.14
Estimate -0.11 · Miss by 25.71%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.08-0.27-0.45-0.64Q1 '25BeatQ2 '25BeatQ3 '25MetQ4 '25MetQ1 '26BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 20, 2025: actual -0.11, estimate -0.12, surprise +8.33%, Beat. Q2 2025, reported May 13, 2025: actual -0.11, estimate -0.12, surprise +8.33%, Beat. Q3 2025, reported Aug 12, 2025: actual -0.12, estimate -0.12, surprise 0.00%, Met estimate. Q4 2025, reported Nov 12, 2025: actual -0.11, estimate -0.11, surprise 0.00%, Met estimate. Q1 2026, reported Mar 12, 2026: actual -0.1, estimate -0.11, surprise +9.09%, Beat. Q2 2026, reported May 11, 2026: actual -0.6, estimate -0.112, surprise -438.02%, Miss. Q3 2026, reported Aug 12, 2026: actual -0.14, estimate -0.111, surprise -25.71%, Miss. Q4 2026, reported Nov 11, 2026: actual —, estimate -0.13, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

11 ratings
Strong buy00%
Buy982%
Hold218%
Sell00%
Strong sell00%

ERAS peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding ERAS

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
178.13M
Weight
0.01%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
133.28M
Weight
1.17%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$165.73+1.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
96M
Weight
0.12%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
56.54M
Weight
0.06%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
34.97M
Weight
0.23%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
26.61M
Weight
0.25%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
22.62M
Weight
0.10%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
22.45M
Weight
0.13%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%

Continue in GoAI

Research ERAS

research.disclaimer